Contrast-Induced Acute Kidney Injury

Journal of the American College of Cardiology

Volumn 68, Issue 13, 2016, Pages 1465-1473

  McCullough, Peter A ^a,b,c   Choi, James P ^b   Feghali, Georges A ^b   Schussler, Jeffrey M ^b   Stoler, Robert M ^b   Vallabahn, Ravi C ^b   Mehta, Ankit ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c THE HEART HOSPITAL BAYLOR PLANO   (United States)

Author keywords

cardiac catheterization; coronary angiography; iodine; percutaneous coronary intervention

Indexed keywords

ACETYLCYSTEINE; AMINOPHYLLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOLDOPAM; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPROMIDE; IOVERSOL; IOXILAN; RENIN INHIBITOR; ROSUVASTATIN; TRIMETAZIDINE; CONTRAST MEDIUM;

CLINICAL PRACTICE; CONTRAST INDUCED NEPHROPATHY; CORONARY ANGIOGRAPHY; DISEASE SEVERITY; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; GLOMERULUS; HEART CATHETERIZATION; HUMAN; INCIDENCE; META ANALYSIS (TOPIC); NONHUMAN; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; URINE VOLUME; ACUTE KIDNEY INJURY; ALGORITHM; CHEMICALLY INDUCED; PATHOPHYSIOLOGY;

ACUTE KIDNEY INJURY; ALGORITHMS; CONTRAST MEDIA; HUMANS;

EID: 84990934116     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.05.099     Document Type: Review

References (33)

1. 1 Amin, A.P., Salisbury, A.C., McCullough, P.A., et al. Trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction. Arch Intern Med 172 (2012), 246–253.
2. 2 Tsai, T.T., Patel, U.D., Chang, T.I., et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI Registry. J Am Coll Cardiol Intv 7 (2014), 1–9.
3. 3 Mehran, R., Aymong, E.D., Nikolsky, E., et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44 (2004), 1393–1399.
4. 4 McCullough, P.A., Radiocontrast-induced acute kidney injury. Nephron Physiol 109 (2008), p61–p72.
5. 5 Seeliger, E., Becker, K., Ladwig, M., et al. Up to 50-fold increase in urine viscosity with iso-osmolar contrast media in the rat. Radiology 256 (2010), 406–414.
6. 6 McCullough, P.A., Capasso, P., Patient discomfort associated with the use of intra-arterial iodinated contrast media: a meta-analysis of comparative randomized controlled trials. BMC Med Imaging, 11, 2011, 12.
7. 7 Liu, Z.Z., Viegas, V.U., Perlewitz, A., et al. Iodinated contrast media differentially affect afferent and efferent arteriolar tone and reactivity in mice: a possible explanation for reduced glomerular filtration rate. Radiology 265 (2012), 762–771.
8. 8 Tervahartiala, P., Kivisaari, L., Kivisaari, R., et al. Structural changes in the renal proximal tubular cells induced by iodinated contrast media. Nephron 76 (1997), 96–102.
9. 9 Liao, J.K., Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110 (2002), 285–288.
10. 10 Sidaway, J.E., Davidson, R.G., McTaggart, F., et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 15 (2004), 2258–2265.
11. 11 Koneth, I., Weishaupt, D., Bachli, E.B., Persistent nephrogram after administration of an isoosmolar contrast medium. Nephrol Dial Transplant 19 (2004), 1654–1655.
12. 12 Guitterez, N.V., Diaz, A., Timmis, G.C., et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol 15 (2002), 349–354.
13. 13 McCullough, P.A., Bouchard, J., Waikar, S.S., et al. Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney injury: executive summary from the tenth consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 182 (2013), 5–12.
14. 14 Kell, D.B., Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics, 2, 2009, 2.
15. 15 Haase, M., Bellomo, R., Haase-Fielitz, A., Novel biomarkers, oxidative stress, and the role of labile iron toxicity in cardiopulmonary bypass-associated acute kidney injury. J Am Coll Cardiol 55 (2010), 2024–2033.
16. 16 Stahl, F., Lepple-Wienhues, A., Kuppinger, M., et al. Electrogenic sodium-bicarbonate cotransport in human ciliary muscle cells. Am J Physiol 262 (1992), C427–C435.
17. 17 Akrawinthawong, K., Ricci, J., Cannon, L., et al. Subclinical and clinical contrast-induced acute kidney injury: data from a novel blood marker for determining the risk of developing contrast-induced nephropathy (ENCINO), a prospective study. Ren Fail 37 (2015), 187–191.
18. 18 Thongprayoon, C., Cheungpasitporn, W., Srivali, N., et al. Acute kidney injury after transcatheter aortic valve replacement: a systematic review and meta-analysis. Am J Nephrol 41 (2015), 372–382.
19. 19 Osprey Medical, Inc. AVERT Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN (AVERT). Bethesda, MD: ClinicalTrials.gov Internet]. 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT01976299?term=osprey&rank=3. Accessed July 12, 2016.
20. 20 Solomon, R., Gordon, P., Manoukian, S.V., et al., BOSS Trial Investigators. Randomized trial of bicarbonate or saline study for the prevention of contrast-induced nephropathy in patients with CKD. Clin J Am Soc Nephrol 10 (2015), 1519–1524.
21. 21 Brar, S.S., Shen, A.Y., Jorgensen, M.B., et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 300 (2008), 1038–1046.
22. 22 Solomon, R., Forced diuresis with the RenalGuard system: impact on contrast induced acute kidney injury. J Cardiol 63 (2014), 9–13.
23. 23 Sadat, U., Usman, A., Gillard, J.H., et al. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. J Am Coll Cardiol 62 (2013), 2167–2175.
24. 24 Subramaniam, R.M., Suarez-Cuervo, C., Wilson, R.F., et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis. Ann Intern Med 164 (2016), 406–416.
25. 25 Weisbord, S.D., Gallagher, M., Kaufman, J., et al. Prevention of contrast-induced AKI: a review of published trials and the design of the Prevention of Serious Adverse Events Following Angiography (PRESERVE) trial. Clin J Am Soc Nephrol 8 (2013), 1618–1631.
26. 26 Li, Y., Liu, Y., Fu, L., et al. Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One, 7, 2012, e34450.
27. 27 Leoncini, M., Toso, A., Maioli, M., et al. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol 63 (2014), 71–79.
28. 28 Han, Y., Zhu, G., Han, L., et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 63 (2014), 62–70.
29. 29 Fried, L.F., Duckworth, W., Zhang, J.H., et al., VA NEPHRON-D Investigators. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 4 (2009), 361–368.
30. 30 Parving, H.H., Brenner, B.M., McMurray, J.J., et al., ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 (2012), 2204–2213.
31. 31 Prasad, A., Ortiz-Lopez, C., Kaye, D.M., et al. The use of the AVERT system to limit contrast volume administration during peripheral angiography and intervention. Catheter Cardiovasc Interv 86 (2015), 1228–1233.
32. 32 Biswas, S., Rowe, E.S., Mosher, G., et al. TCT 138: Veropaque, a novel contrast formulation, mitigates contrast induced acute kidney injury (abstr). J Am Coll Cardiol, 60(17_S), 2012, 10.1016/j.jacc.2012.08.157.
33. 33 Brown, J.R., McCullough, P.A., Contrast nephropathy and kidney injury. Thompson, C.A., (eds.) Textbook of Cardiovascular Intervention, 2014, Springer-Verlag, London, UK, 53–63.